PMC:7212965 / 40052-40173 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T206","span":{"begin":29,"end":37},"obj":"Disease"}],"attributes":[{"id":"A206","pred":"mondo_id","subj":"T206","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"talized patients with severe COVID-19 to receive treatment to lopinavir/ritonavir (n = 99) or placebo (n = 100) for 14 da"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T78","span":{"begin":62,"end":81},"obj":"Chemical"},{"id":"T79","span":{"begin":62,"end":71},"obj":"Chemical"},{"id":"T80","span":{"begin":72,"end":81},"obj":"Chemical"}],"attributes":[{"id":"A78","pred":"chebi_id","subj":"T78","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A79","pred":"chebi_id","subj":"T79","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A80","pred":"chebi_id","subj":"T80","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"}],"text":"talized patients with severe COVID-19 to receive treatment to lopinavir/ritonavir (n = 99) or placebo (n = 100) for 14 da"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1144","span":{"begin":8,"end":16},"obj":"Species"},{"id":"1149","span":{"begin":62,"end":81},"obj":"Chemical"},{"id":"1154","span":{"begin":29,"end":37},"obj":"Disease"}],"attributes":[{"id":"A1144","pred":"tao:has_database_id","subj":"1144","obj":"Tax:9606"},{"id":"A1149","pred":"tao:has_database_id","subj":"1149","obj":"MESH:C558899"},{"id":"A1154","pred":"tao:has_database_id","subj":"1154","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"talized patients with severe COVID-19 to receive treatment to lopinavir/ritonavir (n = 99) or placebo (n = 100) for 14 da"}